Ruxandra Teslo and Jack Scannell note that clinical trial processes and regulatory requirements continue to limit new medicine delivery despite AI advances in molecular design
— Caleb Watney amplified the article amid rising AI abundance claims.
——0——
697223311.3K
Cluster engagement
28 snapshots
Sentiment
Pos100%
Neg0%
Users are optimistic about AI in life sciences because it can reduce administrative costs in drug development and enable faster regulatory pathways such as Phase 1 trials in Australia.